The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
AACR 2022 | Innate cell engager (ICE®) AFM13 combined with cord blood-derived NK cells for R/R CD30+ lymphoma
Yago Nieto, MD, PhD, University of Texas MD Anderson Cancer Center, Houston, TX, discusses a study which investigated the use of the innate cell engager (ICE®) AFM13 combined with preactivated and expanded cord blood (CB)-derived natural killer (NK) cells for the treatment of heavily pretreated patients with relapsed/refractory CD30+ lymphoma. Prof. Nieto first gives a detailed overview of the methodology and patient cohort used in this study, and goes on to discuss some results from the study. Treatment with this novel immunotherapy appears to have a high safety profile, with no cytokine release syndrome (CRS), neurotoxicity or graft versus host disease (GvHD) being observed. Additionally, Prof. Nieto discusses the activity of this product, including complete response (CR) rates and partial remissions observed in patients. To conclude, Prof. Nieto highlights the importance of these results and the role that this novel treatment approach will play in the future treatment of R/R disease. This interview took place at the American Association for Cancer Research Annual Meeting in New Orleans, LA.
